MNKD
Price
$4.54
Change
+$0.01 (+0.22%)
Updated
Apr 17 closing price
Capitalization
1.38B
19 days until earnings call
MNOV
Price
$1.45
Change
-$0.00 (-0.00%)
Updated
Apr 17 closing price
Capitalization
71.12M
21 days until earnings call
Ad is loading...

MNKD vs MNOV

Header iconMNKD vs MNOV Comparison
Open Charts MNKD vs MNOVBanner chart's image
MannKind
Price$4.54
Change+$0.01 (+0.22%)
Volume$1.44M
Capitalization1.38B
Medicinova
Price$1.45
Change-$0.00 (-0.00%)
Volume$6.46K
Capitalization71.12M
MNKD vs MNOV Comparison Chart
Loading...
MNKD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MNOV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
MNKD vs. MNOV commentary
Apr 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MNKD is a Hold and MNOV is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 18, 2025
Stock price -- (MNKD: $4.54 vs. MNOV: $1.45)
Brand notoriety: MNKD and MNOV are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MNKD: 66% vs. MNOV: 39%
Market capitalization -- MNKD: $1.38B vs. MNOV: $71.12M
MNKD [@Biotechnology] is valued at $1.38B. MNOV’s [@Biotechnology] market capitalization is $71.12M. The market cap for tickers in the [@Biotechnology] industry ranges from $282.79B to $0. The average market capitalization across the [@Biotechnology] industry is $2.08B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MNKD’s FA Score shows that 0 FA rating(s) are green whileMNOV’s FA Score has 0 green FA rating(s).

  • MNKD’s FA Score: 0 green, 5 red.
  • MNOV’s FA Score: 0 green, 5 red.
According to our system of comparison, MNKD is a better buy in the long-term than MNOV.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MNKD’s TA Score shows that 3 TA indicator(s) are bullish while MNOV’s TA Score has 5 bullish TA indicator(s).

  • MNKD’s TA Score: 3 bullish, 4 bearish.
  • MNOV’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, MNOV is a better buy in the short-term than MNKD.

Price Growth

MNKD (@Biotechnology) experienced а -2.16% price change this week, while MNOV (@Biotechnology) price change was +14.17% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.02%. For the same industry, the average monthly price growth was -13.21%, and the average quarterly price growth was -24.46%.

Reported Earning Dates

MNKD is expected to report earnings on Aug 06, 2025.

MNOV is expected to report earnings on May 09, 2025.

Industries' Descriptions

@Biotechnology (+7.02% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MNKD($1.38B) has a higher market cap than MNOV($71.1M). MNKD YTD gains are higher at: -29.393 vs. MNOV (-30.952). MNKD has higher annual earnings (EBITDA): 77.5M vs. MNOV (-12.65M). MNKD has more cash in the bank: 197M vs. MNOV (40.4M). MNOV has less debt than MNKD: MNOV (194K) vs MNKD (47.7M). MNKD has higher revenues than MNOV: MNKD (286M) vs MNOV (0).
MNKDMNOVMNKD / MNOV
Capitalization1.38B71.1M1,941%
EBITDA77.5M-12.65M-612%
Gain YTD-29.393-30.95295%
P/E Ratio45.40N/A-
Revenue286M0-
Total Cash197M40.4M488%
Total Debt47.7M194K24,588%
FUNDAMENTALS RATINGS
MNKD vs MNOV: Fundamental Ratings
MNKD
MNOV
OUTLOOK RATING
1..100
5813
VALUATION
overvalued / fair valued / undervalued
1..100
60
Fair valued
48
Fair valued
PROFIT vs RISK RATING
1..100
38100
SMR RATING
1..100
10092
PRICE GROWTH RATING
1..100
6376
P/E GROWTH RATING
1..100
96100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MNOV's Valuation (48) in the Biotechnology industry is in the same range as MNKD (60). This means that MNOV’s stock grew similarly to MNKD’s over the last 12 months.

MNKD's Profit vs Risk Rating (38) in the Biotechnology industry is somewhat better than the same rating for MNOV (100). This means that MNKD’s stock grew somewhat faster than MNOV’s over the last 12 months.

MNOV's SMR Rating (92) in the Biotechnology industry is in the same range as MNKD (100). This means that MNOV’s stock grew similarly to MNKD’s over the last 12 months.

MNKD's Price Growth Rating (63) in the Biotechnology industry is in the same range as MNOV (76). This means that MNKD’s stock grew similarly to MNOV’s over the last 12 months.

MNKD's P/E Growth Rating (96) in the Biotechnology industry is in the same range as MNOV (100). This means that MNKD’s stock grew similarly to MNOV’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MNKDMNOV
RSI
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
71%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
86%
Bearish Trend 1 day ago
77%
Momentum
ODDS (%)
Bearish Trend 1 day ago
72%
Bullish Trend 1 day ago
71%
MACD
ODDS (%)
Bearish Trend 1 day ago
87%
Bullish Trend 1 day ago
62%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
76%
Bullish Trend 1 day ago
72%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
75%
Bearish Trend 1 day ago
78%
Advances
ODDS (%)
N/A
Bullish Trend 5 days ago
71%
Declines
ODDS (%)
Bearish Trend 11 days ago
79%
Bearish Trend 12 days ago
83%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
86%
Bullish Trend 1 day ago
78%
Aroon
ODDS (%)
Bearish Trend 1 day ago
71%
Bearish Trend 1 day ago
84%
View a ticker or compare two or three
Ad is loading...
MNKD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MNOV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PEAPX25.32N/A
N/A
Principal Glb Emerging Markets R3
STOFX23.96N/A
N/A
Allspring Large Cap Growth C
SWASX6.13N/A
N/A
Schwab Global Real Estate
FBPEX24.57N/A
N/A
Cantor Fitzgerald Equity Div Plus Inst
JFRNX49.36-0.33
-0.66%
Janus Henderson Forty N

MNKD and

Correlation & Price change

A.I.dvisor indicates that over the last year, MNKD has been loosely correlated with VCYT. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if MNKD jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MNKD
1D Price
Change %
MNKD100%
+0.22%
VCYT - MNKD
44%
Loosely correlated
-1.24%
LXRX - MNKD
42%
Loosely correlated
+1.96%
INSM - MNKD
40%
Loosely correlated
+3.49%
BLUE - MNKD
38%
Loosely correlated
-0.24%
GBIO - MNKD
37%
Loosely correlated
+13.03%
More

MNOV and

Correlation & Price change

A.I.dvisor indicates that over the last year, MNOV has been loosely correlated with FATE. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if MNOV jumps, then FATE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MNOV
1D Price
Change %
MNOV100%
N/A
FATE - MNOV
36%
Loosely correlated
+5.71%
MNKD - MNOV
30%
Poorly correlated
+0.22%
ALT - MNOV
29%
Poorly correlated
+3.41%
VIR - MNOV
29%
Poorly correlated
+1.20%
TIL - MNOV
28%
Poorly correlated
+1.01%
More